ClinicalTrials.gg
Status unknownNCT02652351Updated May 23, 2016

Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis

A Phase 1 interventional study of Human umbilical cord mesenchymal stem cells in Hepatic Cirrhosis, sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-23.

Sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
114th of 127
20 · median 120
Started
2016
with 8 others
Phase 1
11 of 214
2 open now
Registered
55th of 214
by date

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 114th largest by planned enrollment of the 127 interventional ones that give a count, is one of 9 that started in 2016, is one of 11 in phase 1, and was the 55th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Hepatic Cirrhosis.

Read the detailed description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of Hepatic Cirrhosis.

To investigate the effects of hUC-MSC treatment for Hepatic Cirrhosis, 20 patients with Hepatic Cirrhosis will be enrolled and receive 4 times of hUC-MSC transplantation.

03

Conditions studied

  • Hepatic Cirrhosis

Browse trials for

Keywords

  • Stem cell
  • Human Umbilical Cord Mesenchymal Stem Cell
  • Mesenchymal Stem Cell
  • Hepatic Cirrhosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient who have signed the document;
  • Clinical, radiological, or biochemical evidence of liver cirrhosis.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or lactating mothers;
  • Patients who have received any anti-inflammatory drugs including herb-drug within 14 days;
  • Patients who received any drug by intra-articular injection for treatment within 2 months prior to this enrollment;
  • Patients with positive human immunodeficiency () at screening indicative of current of pass infection;
  • Abnormal blood coagulation, combine other tumor or special condition;
  • Patients who had participated in other clinical trials within three months prior to this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    hUC-MSC treatment

    Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.

    Biological: Human umbilical cord mesenchymal stem cells

Interventions

  • A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.

    Also known as: hUC-MSC

06

What researchers measure

Primary outcomes

  1. Severity of adverse events

    According to National Cancer Institute Common Terminology Criteria for Adverse Events(NCI-CTCAE)

    Time frame: 12 months

Secondary outcomes

  1. Hepatic function

    Include AST, ALT, T-Bil and A/G.

    Time frame: 1, 3 ,6 and 12 months

  2. Liver fibrosis index

    The level of Hyaluronidase,Laminin,Procollagen Ⅲ and Collagen Type IV in serum.

    Time frame: 1, 3 ,6 and 12 months

07

Study locations

1 of 1 sites recruiting
  • The second Affiliated Hospital of University of Soth China
    Hengyang, Hunan 431224, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of May 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2016
First posted
Jan 11, 2016
Start
Mar 2016
Primary completionEst.
May 2016
CompletionEst.
Oct 2016
Last update
May 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02652351
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators
The Second Hospital University of South China
Responsible party
Sponsor
First posted
Jan 11, 2016
Start date
Mar 2016
Primary completion
May 2016 (estimated)
Completion
Oct 2016 (estimated)
Last update
May 23, 2016

Study contacts

Jin S Cao, lab master
Contact
CaoJS@hornetcon.com
+86 0734-53137955
Gang Chen, Professor
principal investigator · The second Affiliated Hospital of University of Soth China

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion